Antengene Corp., a biopharmaceutical company dedicated to developing first-in-class therapeutics in hematology and oncology, and WuXi Biologics, have signed a strategic Memorandum of Understanding (MoU) for the development and production of novel drugs, and to jointly promote R&D of innovative oncology therapies. “We are very glad to launch a strategic cooperation with WuXi Biologics. This cooperation is a timely decision. WuXi Biologics has first-class biopharmaceutical capabilitie...